Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Daniel Spinosa
University of Colorado Anschutz Medical Campus
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
27
TOTAL CITATIONS
0
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
Bevacizumab Beyond Progression: Impact of Subsequent Bevacizumab Re-Treatment in Patients with Ovarian, Fallopian Tube, and Peritoneal Cancer after Progression
Number of pages: 25
Posted: 08 Oct 2024
Amma Asare
,
Rebecca A. Previs
, Daniel Spinosa,
Bryan Fellman
,
Amelia Scott
,
Isabelle Mulder
,
Jean Hansen Siedel MD
,
Lauren Cobb
,
Pamela Soliman
,
Anil Sood
,
Robert Coleman
,
Angeles Alvarez Secord
and
Shannon N. Westin
affiliation not provided to SSRN
,
affiliation not provided to SSRN
, University of Colorado Anschutz Medical Campus, University of Texas at Houston - MD Anderson Cancer Center, Duke University - Medical Center, Columbia University College of Physicians and Surgeons,
affiliation not provided to SSRN
,
affiliation not provided to SSRN
,
affiliation not provided to SSRN
, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine,
affiliation not provided to SSRN
, Duke University and University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine
Downloads
27
(1,359,097)
View PDF
Download
Abstract:
ovarian cancer, fallopian tube cancer, bevacizumab, angiogenesis inhibitors
Feedback